Given the established protumorigenic effects of LL-37 (24, 25, 29), our results emphasize the necessity for monitoring serum hCAP18/LL-37 dynamics during clinical trials evaluating vitamin D-based therapies for HCC patients. The gene discussed is CAMP; the disease is hepatocellular carcinoma.